- Home
- QNRX vs GTBP Comparison
QNRX vs GTBP Comparison
Compare QNRX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- GTBP
- Stock Information
- Founded
- QNRX 2018
- GTBP 1965
- Country
- QNRX United States
- GTBP United States
- Employees
- QNRX N/A
- GTBP N/A
- Industry
- QNRX Medical/Dental Instruments
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- GTBP Health Care
- Exchange
- QNRX Nasdaq
- GTBP Nasdaq
- Market Cap
- QNRX 5.5M
- GTBP 5.5M
- IPO Year
- QNRX N/A
- GTBP N/A
- Fundamental
- Price
- QNRX $8.89
- GTBP $2.26
- Analyst Decision
- QNRX
- GTBP Strong Buy
- Analyst Count
- QNRX 0
- GTBP 1
- Target Price
- QNRX N/A
- GTBP $11.00
- AVG Volume (30 Days)
- QNRX 8.2K
- GTBP 114.2K
- Earning Date
- QNRX 08-07-2025
- GTBP 08-13-2025
- Dividend Yield
- QNRX N/A
- GTBP N/A
- EPS Growth
- QNRX N/A
- GTBP N/A
- EPS
- QNRX N/A
- GTBP N/A
- Revenue
- QNRX N/A
- GTBP N/A
- Revenue This Year
- QNRX N/A
- GTBP N/A
- Revenue Next Year
- QNRX N/A
- GTBP N/A
- P/E Ratio
- QNRX N/A
- GTBP N/A
- Revenue Growth
- QNRX N/A
- GTBP N/A
- 52 Week Low
- QNRX $5.01
- GTBP $1.72
- 52 Week High
- QNRX $54.95
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- QNRX 51.38
- GTBP 38.82
- Support Level
- QNRX $8.60
- GTBP $1.91
- Resistance Level
- QNRX $9.40
- GTBP $3.73
- Average True Range (ATR)
- QNRX 0.50
- GTBP 0.33
- MACD
- QNRX -0.05
- GTBP -0.16
- Stochastic Oscillator
- QNRX 46.11
- GTBP 19.59
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.